Products

One of our patented products, a class of the Aflatoxin-detocifizymes, can detoxify the toxicities caused by the Aflatoxin B1 that is considered the most lethal substance that can cause cancer.It is listed by WHO as 1A class carcinogen that poses a great threat to human health. The foods that contain aflatoxins include peanut, peanut kernel, peanut oil, seed, corn, or feed, etc. Detoxification of aflatoxin by using our Aflatoxin-detocifizyme a bio-product in the foods should have great economic values and contribution in our human public health.

According to WHO, the global economy loses due to disease of the central nervous system (CNS), i.e., the depression and anxiety, is more than USD 1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD 16 trillion in 2030; most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and amyotrophic lateral sclerosis. In addition, the number of new cases of CNS cancers was 23,890 whereas the number of deaths was 18,020 in the U.S. in 2020 according to National Cancer Institute estimates. The global CNS markets size is expected to reach USD 205.0 billion by 2028, according to a new report by Grand View Research, Inc.; the market is expected to expand at a CAGR of 7.4% from 2021 to 2028. High unmet medical needs and government initiatives to reduce the disease burden are driving the market for CNS therapeutic over the forecast period.

Radiation therapy (RT) treats many types of cancer effectively including brain tumors, breast cancer, head and neck tumors, lung, and chest tumor, etc.; however people who get radiation to the head and neck might have serious side effects such as soreness (or even open sores) in the mouth or throat, dry mouth, trouble swallowing (cause of death), etc.; these significantly disrupt the qualities of the people’s life after RT, AQP treatment therefore could provide the opportunity to reduce the side-effects to recover those symptoms. In addition, our AQP products could be extended to burn care and cosmetic applications. The global burn care market size was valued at USD 2.1 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.9% from 2021 to 2028. The demand for burn care products is on a rise owing to the rising incidence of burn, high demand for skin grafts, growing awareness regarding treatment options, and increasing technological advancements.

To develop our AV-series products, we have invented core ingredients for several nutrition supplements and cosmetic reagents based on peptides, nucleotides, aquaporin proteins (AQP), and stem cells.
 

• UMG has developed and manufactured a numbers of special nutrition supplements such as AV-18, AV-19, AV-20; particularly at the beginning of COVID-19 pandemic, Dr. Lai collaborated with Vast Sea Biotechnology Inc to develop and manufacture AVL-19. This product was filed in patent applications and is used to support human immunity.